Bioblast Pharma (ORPN) Competitors

Galmed Pharmaceuticals (NASDAQ:GLMD) and Bioblast Pharma (NASDAQ:ORPN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

Is GLMD or ORPN more profitable?

Bioblast Pharma's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-28.75%	-24.98%
Bioblast Pharma	N/A	N/A	N/A

Does the media prefer GLMD or ORPN?

In the previous week, Galmed Pharmaceuticals had 3 more articles in the media than Bioblast Pharma. MarketBeat recorded 3 mentions for Galmed Pharmaceuticals and 0 mentions for Bioblast Pharma. Galmed Pharmaceuticals' average media sentiment score of 1.19 beat Bioblast Pharma's score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Galmed Pharmaceuticals	Positive
Bioblast Pharma	Neutral

Which has more volatility & risk, GLMD or ORPN?

Galmed Pharmaceuticals has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, Bioblast Pharma has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.

Does the MarketBeat Community prefer GLMD or ORPN?

Galmed Pharmaceuticals received 230 more outperform votes than Bioblast Pharma when rated by MarketBeat users. However, 78.23% of users gave Bioblast Pharma an outperform vote while only 63.69% of users gave Galmed Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Galmed Pharmaceuticals	Outperform Votes 442 63.69%	Underperform Votes 252 36.31%
Bioblast Pharma	Outperform Votes 212 78.23%	Underperform Votes 59 21.77%

Do insiders and institutionals have more ownership in GLMD or ORPN?

76.1% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 4.5% of Bioblast Pharma shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has better earnings and valuation, GLMD or ORPN?

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$6.91M	-$16.66	-0.18
Bioblast Pharma	N/A	N/A	-$5.94M	N/A	N/A

Summary

Galmed Pharmaceuticals and Bioblast Pharma tied by winning 5 of the 10 factors compared between the two stocks.